Status:

ACTIVE_NOT_RECRUITING

A Phase 1 Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r/r DLBCL

Lead Sponsor:

Otsuka Pharmaceutical Co., Ltd.

Conditions:

Relapsed or Refractory Diffuse Large B-cell Lymphoma

Eligibility:

All Genders

20-80 years

Phase:

PHASE1

Brief Summary

To investigate the tolerability and safety of OPB-111077 in combination with bendamustine and rituximab in patients with r/r DLBCL.

Eligibility Criteria

Inclusion

  • Patients with a definite diagnosis of Diffuse large B-cell lymphoma(DLBCL)
  • Patients who have received at least initial standard treatment
  • Patients with measurable lesions (based on International Working Group \[IWG\] 2014 criteria)
  • Patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1
  • \<Only for dose-expansion stage\>
  • Patients who are pathologically diagnosed as CD20 positive lymphoma
  • Patients who have a history of being treated with 1 to 5 regimens of previous chemotherapy for the underlying disease

Exclusion

  • Patients who are candidates for autologous or allogeneic hematopoietic stem cell transplantation
  • Patients who were refractory to initial standard treatment
  • Patients who have a history of bendamustine administration and are intolerant to bendamustine
  • Patients with central nervous system (CNS) involvement of lymphoma or with a history of CNS involvement of lymphoma
  • Patients diagnosed with DLBCL transformed from low-grade B-cell non-Hodgkin's lymphoma (NHL)
  • \<Only for dose-expansion stage\>
  • \- Patients who have a history of rituximab administration and are intolerant to rituximab

Key Trial Info

Start Date :

November 22 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 1 2025

Estimated Enrollment :

36 Patients enrolled

Trial Details

Trial ID

NCT04049825

Start Date

November 22 2019

End Date

March 1 2025

Last Update

May 2 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Yamagata University Hospital

Yamagata, Japan